To clarify the biological behavior, the flowcytometric nuclear DNA content, S-phase fraction(SPF) and proliferating cells by immunostaining of @entity1364 were investigated in 13 @entity1 with @entity2742 (10 @entity652 , 2 @entity1373 and 1 @entity5 ) and 10 normal controls. No. of parathyroid glands or tissues examined was as follows: 10 @entity652 , three @entity1373 from one case, one primary and one recurrent @entity189 of the same case, two @entity1373 from one case and 10 normal glands. All controls and @entity1373 showed diploid DNA, but the 10 @entity652 @entity2007 in four and diploid in six. The @entity189 showed diploid in the @entity75 , @entity2007 in the recurrence. DNA index in recurrent @entity189 was higher than that in @entity652 . SPF in primary and recurrent @entity5 and @entity652 as higher than that in the others. The expression of @entity1364 in all @entity2742 except for @entity1373 was higher than that in normal controls. In conclusion, there might be some premalignant potential in the @entity652 from the view of DNA flowcytometry and @entity1364 immunostaining. Therefore, @entity652 should be strictly followed up.

Nuclear DNA content, S-phase fraction analysis and expression of XXXX ( @entity1364 ) of normal and hyperplastic/neoplastic parathyroid glands.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1364 :: ('5111', 'Gene') :: ['proliferating cell nuclear antigen(PCNA)', 'PCNA'] @entity2007 :: ('MESH:D000782', 'Disease') :: ['aneuploid'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer'] @entity75 :: ('MESH:D001927', 'Disease') :: ['primary lesion'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasias', 'secondary hyperplasias'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'aneuploid adenoma'] @entity2742 :: ('MESH:D006961', 'Disease') :: ['hyperparathyroidism']
@entity1364 :: (5111,Gene) :: ['proliferating cell nuclear antigen']
